• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

    2/12/24 4:26:50 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRLD alert in real time by email
    SC 13G/A 1 d749523dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Schedule 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Prelude Therapeutics Incorporated

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    74065P101

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on following pages)

     

     

     


    CUSIP #74065P101   Schedule 13G   Page 2 of 5

     

     1   

     NAME OF REPORTING PERSONS

     

     Krishna Vaddi

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     4,908,086(1)

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     4,908,086(1)

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,908,086(1)

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     11.1%(2)

    12  

     TYPE OF REPORTING PERSON

     

     IN

     

    (1)

    Consists of (i) 3,260,216 shares of voting common stock held by the Reporting Person, of which (a) 27,008 shares are unvested as of December 31, 2023, and subject to forfeiture to the Issuer if the Reporting Person ceases to provide service to the Issuer prior to the vesting of the shares and (b) 2,192,941 shares of voting common stock are subject to options that are exercisable within 60 days of December 31, 2023, (ii) 120,665 shares of voting common stock held by Sidus Ventures, LLC, (iii) 423,655 shares of voting common stock held by Dolphin City Trust, (iv) 551,776 shares of voting common stock held by Blue Sky Trust and (v) 551,774 shares of voting common stock held by Brocade Trust. The Reporting Person is the manager of Sidus Ventures, LLC and may be deemed to have beneficial ownership over the securities held by Sidus Ventures, LLC. The Reporting Person is the beneficiary of Dolphin City Trust and may be deemed to have beneficial ownership over the securities held by Dolphin City Trust. The Reporting Person is the investment advisor for each of the Blue Sky Trust and the Brocade Trust, and may be deemed to have beneficial ownership over the securities held by each of the Blue Sky Trust and the Brocade Trust.

    (2)

    The percentage reported in row 11 is calculated in accordance with Rule 13d-3 based on the aggregate number of shares of common stock beneficial owned by the Reporting Person and an aggregate of 42,063,995 shares of common stock entitled to vote outstanding as of December 31, 2023, as reported by the Issuer to the Reporting Person, plus the number of shares of stock options held by the Reporting Person that are exercisable within 60 days of December 31, 2023, which are treated as converted into common stock only for the purpose of computing the percentage ownership of the Reporting Person.


    CUSIP #74065P101   Schedule 13G   Page 3 of 5

     

    SCHEDULE 13G

    CUSIP #74065P101

    ITEM 1(A).

    NAME OF ISSUER:

    Prelude Therapeutics Incorporated (the “Issuer”)

     

    ITEM 1(B).

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

    175 Innovation Boulevard

    Wilmington, Delaware 19805

     

    ITEM 2(A).

    NAME OF PERSONS FILING

    Krishna Vaddi (the “Reporting Person”)

     

    ITEM 2(B).

    ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

    The address of the principal business office of the Reporting Person is:

    c/o Prelude Therapeutics Incorporated

    175 Innovation Boulevard

    Wilmington, Delaware 19805

     

    ITEM 2(C).

    CITIZENSHIP:

    United States

     

    ITEM 2(D).

    TITLE OF CLASS OF SECURITIES:

    Common Stock, par value $0.0001 per share

     

    ITEM 2(E)

    CUSIP NUMBER:

    74065P101

     

    ITEM 3.

    IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

    (a)

    ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

     

    (b)

    ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)

    ☐ Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

     

    (d)

    ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

    (e)

    ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)

    ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)

    ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)

    ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)

    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)

    ☐ A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

     

    (k)

    ☐ Group, in accordance with §240.13d–1(b)(1)(ii)(K).


    CUSIP #74065P101   Schedule 13G   Page 4 of 5

     

    If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution:________________________________.

    Not applicable.

     

    ITEM 4.

    OWNERSHIP:

    (a) Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person.

    (b) Percent of Class:

    See Row 11 of cover page for each Reporting Person.

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person.

    (ii) Shared power to vote or to direct the vote:

    See Row 6 of cover page for each Reporting Person.

    (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page for each Reporting Person.

    (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person.

     

    ITEM 5.

    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

    Not applicable.

     

    ITEM 6.

    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

    Not applicable.

     

    ITEM 7.

    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:

    Not applicable.

     

    ITEM 8.

    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

    Not applicable.

     

    ITEM 9.

    NOTICE OF DISSOLUTION OF GROUP:

    Not applicable.

     

    ITEM 10.

    CERTIFICATION:

    Not applicable.


    CUSIP #74065P101   Schedule 13G   Page 5 of 5

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 12, 2024

     

    By:  

    /s/ Krishna Vaddi

      Krishna Vaddi
    Get the next $PRLD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRLD

    DatePrice TargetRatingAnalyst
    9/19/2024$5.00Neutral → Buy
    H.C. Wainwright
    6/20/2024$3.00Equal Weight → Underweight
    Barclays
    3/13/2024$7.00Mkt Outperform
    JMP Securities
    2/20/2024$5.00Buy → Neutral
    H.C. Wainwright
    12/19/2023$10.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    11/21/2022$8.00 → $6.00Neutral → Underperform
    BofA Securities
    9/9/2022$19.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    7/29/2022$9.00Buy
    Jefferies
    More analyst ratings

    $PRLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Prelude Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Prelude Therapeutics from Neutral to Buy and set a new price target of $5.00

      9/19/24 7:51:24 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics downgraded by Barclays with a new price target

      Barclays downgraded Prelude Therapeutics from Equal Weight to Underweight and set a new price target of $3.00

      6/20/24 7:37:20 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Prelude Therapeutics with a new price target

      JMP Securities initiated coverage of Prelude Therapeutics with a rating of Mkt Outperform and set a new price target of $7.00

      3/13/24 7:41:41 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

      WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. Jefferies Global Healthcare Conference 2025:On Thursday, June 5, 2025, at 3:10 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. Goldman Sachs 46th Annual Global Healthcare Conference:On Wednesday, June 11, 2025, at 9:20 a.m. ET, Kris, Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. Live webcasts of the fireside chats can be accessed on the Company's

      6/2/25 7:30:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude's once daily, oral SMARCA2 degrader, PRT7732 is advancing rapidly, and an initial data update is anticipated in the second half of 2025 Current cash runway into the second quarter of 2026 with $103.1 million in cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025  WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported its financial results for

      5/6/25 4:05:00 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics to Participate in Citizens Life Sciences Conference

      WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025. On Wednesday, May 7, 2025, at 11:00 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Peggy Scherle, Ph.D., Chief Scientific Officer will participate in a fireside chat. A live webcast of the fireside chat can be accessed on the Company's website under Events and Presentations. The recording will be archived and available on the Compa

      5/1/25 7:30:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Chemistry Officer Combs Andrew bought $69,250 worth of shares (100,000 units at $0.69), increasing direct ownership by 26% to 480,123 units (SEC Form 4)

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      3/27/25 4:40:54 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Vaddi Krishna bought $467,438 worth of shares (675,000 units at $0.69), increasing direct ownership by 51% to 1,999,296 units (SEC Form 4)

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      3/27/25 4:37:44 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Vaddi Krishna bought $14,909 worth of shares (20,416 units at $0.73), increasing direct ownership by 2% to 1,324,296 units (SEC Form 4)

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      3/24/25 5:03:10 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Baker Bros. Advisors Lp

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      6/13/25 4:45:31 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Scherer Paul C

      3 - Prelude Therapeutics Inc (0001678660) (Issuer)

      6/13/25 4:43:00 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sandor Victor

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      6/13/25 4:15:50 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Financials

    Live finance-specific insights

    See more
    • Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

      -  Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation -  At doses studied to date, PRT3789 was generally well-tolerated with no dose-limiting toxicities or study drug-related serious adverse events -  Company to host investor conference call and webcast on Friday, September 13, 2024 at 12:00 PM EST WILMINGTON, Del., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the first interim clinical

      9/13/24 10:00:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

      PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST) Prelude will host an investor webcast on September 13, 2024, 6:00 PM CEST, (12:00 PM EST) WILMINGTON, Del., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of an abstract regarding PRT3789 at the European Society of Medical Oncology (ESMO) Congress 2024 taking place in Barcelona, Spain September 13-17, 2024. The abstract can be found on the ESMO 2024 website

      9/9/24 7:30:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

      PRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients Phase 1 Dose Expansion Ongoing in Biomarker-Selected Solid Tumor and Hematologic Malignancy Expansion Cohorts for PRT543; Dose Expansion Portion of Phase 1 Trial of PRT811 to Commence 4Q21 with Data Readouts Anticipated for Both Programs in 2022 PRT2527 IND Cleared by FDA; Phase 1 Clinical Trial Evaluating IV Monotherapy in Patients with Selected Solid Tumors Anticipated to Begin by Year-End Strong Cash, Cash Equivalents and Marketable Securities Position of $320 Million to Support Clinical and Discovery Pipeline Advance

      11/12/21 8:00:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Prelude Therapeutics Incorporated

      SCHEDULE 13D/A - Prelude Therapeutics Inc (0001678660) (Subject)

      6/13/25 5:21:09 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics Incorporated filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Prelude Therapeutics Inc (0001678660) (Filer)

      6/13/25 4:10:27 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Prelude Therapeutics Incorporated

      SCHEDULE 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

      5/15/25 5:20:50 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Leadership Updates

    Live Leadership Updates

    See more
    • Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

      Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024 WILMINGTON, Del., May 10, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude") (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022, and provided an update on recent clinical and development pipeline progress. "Prelude continues to make great progress in discovering and advancing a diverse pipeline of differentiated small molecu

      5/10/22 8:00:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics Reports Full Year 2021 Financial Results

      Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients Objectives for 2022: Focused on demonstrating proof-of-concept clinical data for lead pipeline compounds and continued advancement of Prelude's diverse precision oncology pipeline Cash runway guidance extended to 2H/2024 WILMINGTON, Del., March 16, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2021. "With Prelude's core competencies in cancer biology an

      3/16/22 7:30:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer

      WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) a clinical-stage precision oncology company, today announced that Jane Huang, M.D., has been appointed to the newly created position of President and Chief Medical Officer, effective on April 4, 2022. Dr. Huang is currently Chief Medical Officer, Hematology, at BeiGene, Ltd., a global, science-driven biotechnology company developing oral small molecules and monoclonal antibodies for cancer. "We are pleased to announce that Dr. Huang will be joining Prelude. Jane's deep experience in oncology drug development and her strategic leadership throughout the lifecycle of multiple products resulti

      3/9/22 8:00:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

      SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

      2/13/24 1:34:34 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

      SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

      2/12/24 5:30:07 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

      SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

      2/12/24 4:26:50 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care